论文部分内容阅读
目的抗血管生成药物贝伐珠单抗联合化疗可延长结直肠癌肝转移患者的总生存和无进展生存,且安全性良好,本文重点研究贝伐珠单抗联合化疗治疗结直肠癌肝转移的效果。方法回顾性记录50例患者治疗前后的临床分期,并进行治疗效果评价,为临床治疗提供依据,以期提高直肠癌肝转移的生存率。分别对50例患者进行1年和2年短期随访,记录生存率和复发率。结果综合治疗组和化学治疗组的1年和2年生存率分别为95.2%、52.4%和79.3%、34.5%。χ2检验有统计学差异(χ2=6.62、7.10 P<0.05);局部复发率两组为28.6%、62.1%。χ2检验有统计学差异(χ2=5.89,P<0.05)。结论综合治疗结直肠癌肝转移患者,可以明显提高患者的近期生存率,降低局部复发率,毒副反应较小,临床获益较大。在转移性肿瘤的治疗中应当把治疗分为全身治疗和局部治疗,全身治疗放在第一位,在进行全身治疗的基础上再进行局部治疗效果更好,否则转移灶会不断增多。
The purpose of anti-angiogenic drug bevacizumab combined with chemotherapy can prolong the overall survival and progression-free survival of patients with liver metastases of colorectal cancer, and good safety, this paper focuses on the combination of bevacizumab and chemotherapy in the treatment of liver metastases of colorectal cancer effect. Methods The clinical staging of 50 patients before and after treatment was retrospectively reviewed. The therapeutic effect was evaluated to provide the basis for clinical treatment in order to improve the survival rate of liver metastasis of rectal cancer. 50 patients were short-term follow-up of 1 year and 2 years, record the survival rate and recurrence rate. Results The 1-year and 2-year survival rates of the combination therapy group and the chemotherapy group were 95.2%, 52.4% and 79.3%, 34.5%, respectively. χ2 test was statistically significant (χ2 = 6.62,7.10 P <0.05); the local recurrence rate was 28.6% in both groups, 62.1%. χ2 test was statistically significant (χ2 = 5.89, P <0.05). Conclusion The comprehensive treatment of patients with liver metastases of colorectal cancer can significantly improve the short-term survival rate of patients, reduce the local recurrence rate, fewer side effects, greater clinical benefit. In the treatment of metastatic tumors should be divided into systemic treatment and local treatment, systemic treatment on the first place in the systemic treatment based on the local treatment and then better, otherwise the metastasis will continue to increase.